Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings?

Key Takeaways GILD reports Q4 results on Feb. 10, with consensus estimates of $7.57B in sales and $1.83 in EPS.Gilead's HIV franchise remains the growth engine, led by Biktarvy, Descovy and contributions from Yeztugo.GILD faces pressure in cell therapy sales, while liver disease drugs and Trodelvy support revenues.Biotech bigwig Gilead Sciences, Inc. (GILD) is scheduled to report fourth-quarter and full-year 2025 results on Feb. 10, after market close. The Zacks Consensus Estimate for fourth-quarter sales a ...